These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 34731491)

  • 1. BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.
    Lombardo KA; Obradovic A; Singh AK; Liu JL; Joice G; Kates M; Bishai W; McConkey D; Chaux A; Eich ML; Rezaei MK; Netto GJ; Drake CG; Tran P; Matoso A; Bivalacqua TJ
    J Pathol; 2022 Feb; 256(2):223-234. PubMed ID: 34731491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model.
    de Queiroz NMGP; Marinho FV; de Araujo ACVSC; Fahel JS; Oliveira SC
    Sci Rep; 2021 Aug; 11(1):15648. PubMed ID: 34341449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
    Atallah A; Grossman A; Nauman RW; Paré JF; Khan A; Siemens DR; Cotechini T; Graham CH
    Int J Cancer; 2024 Jul; 155(2):352-364. PubMed ID: 38483404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.
    Nunez-Nateras R; Castle EP; Protheroe CA; Stanton ML; Ocal TI; Ferrigni EN; Ochkur SI; Jacobsen EA; Hou YX; Andrews PE; Colby TV; Lee NA; Lee JJ
    Urol Oncol; 2014 Jan; 32(1):45.e23-30. PubMed ID: 24055426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG; Lee SJ; Huh JS; Lee JH
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
    Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A
    Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.
    Biot C; Rentsch CA; Gsponer JR; Birkhäuser FD; Jusforgues-Saklani H; Lemaître F; Auriau C; Bachmann A; Bousso P; Demangel C; Peduto L; Thalmann GN; Albert ML
    Sci Transl Med; 2012 Jun; 4(137):137ra72. PubMed ID: 22674550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
    Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
    Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.
    Chevalier MF; Schneider AK; Cesson V; Dartiguenave F; Lucca I; Jichlinski P; Nardelli-Haefliger D; Derré L
    Eur Urol; 2018 Nov; 74(5):540-544. PubMed ID: 30033046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
    Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K
    Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory T Cells and Tumor-Associated Macrophages in the Tumor Microenvironment in Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacille Calmette-Guérin: A Long-Term Follow-Up Study of a Japanese Cohort.
    Miyake M; Tatsumi Y; Gotoh D; Ohnishi S; Owari T; Iida K; Ohnishi K; Hori S; Morizawa Y; Itami Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Shimada K; Konishi N; Tanaka N; Fujimoto K
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29048388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacillus Calmette-Guérin immunotherapy induces an efficient antitumor response to control murine melanoma depending on MyD88 signaling.
    Borges VM; Marinho FV; Caldeira CVA; de Queiroz NMGP; Oliveira SC
    Front Immunol; 2024; 15():1380069. PubMed ID: 38835781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
    Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
    J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
    Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
    Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
    J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical BCG Induces CD4
    Kates M; Nirschl T; Sopko NA; Matsui H; Kochel CM; Reis LO; Netto GJ; Hoque MO; Hahn NM; McConkey DJ; Baras AS; Drake CG; Bivalacqua TJ
    Cancer Immunol Res; 2017 Jul; 5(7):594-603. PubMed ID: 28588015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.